Nu.q® discover expands global adoption and epigenetic innovation

Henderson, nev., july 16, 2025 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, today provides an update on the significant commercial and scientific progress of its nu.q® discover program.

VNRX Ratings Summary

VNRX Quant Ranking